Eli Lilly CEO John Lechleiter Rules Out Mega-merger Or Major Push Into Generics, Outlines Strategy Aimed At China's 21st Century Rise In An Interview With PharmAsia News
This article was originally published in PharmAsia News
Executive Summary
Eli Lilly's chief executive officer, John Lechleiter, recently discussed with PharmAsia News' China bureau the Indianapolis-headquartered outfit's strategy to benefit from the rapid rise of China's economy and scientific capabilities while also spelling out that the company would not seek to engineer any mega-merger ahead. The organic chemist who heads Lilly suggested in a keynote talk in Shanghai that Chinese scientists would increasingly help shape "the century of human medicine" if the government strengthens the intellectual property regime in order to unleash innovation (PharmAsia News, April 02, 2010), and expanded on those ideas in a follow-up interview.